Article

COA Responds to CMS Proposal to Ease Protections on 6 Drug Classes

Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.

Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer. According to COA, for the first time ever, Medicare patients with cancer and other serious diseases will no longer have guaranteed access to potentially life-saving drugs and instead will have to go through step therapy and formulary restrictions.

Noting their support of the administration's efforts to lower drug prices, COA argues that weakening or dismantling protected classes of drugs is too far. Read the full press release from Jeff Vacirca, MD, FACP, president of COA.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Dr Margrit Wiesendanger
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Margrit Wiesendanger
Tom Belmon, CAP, GPBCH
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo